Brief: Sprint Bioscience Reports Positive Results From The Vrk1 Program
17/03/2026 07:11
March 17 (Reuters) - Sprint Bioscience AB SPRINT.ST: REPORTS POSITIVE RESULTS FROM THE VRK1 PROGRAM VRK1 INHIBITION SELECTIVELY KILLS VRK2-LOW GLIOBLASTOMA CELLS CELLS WITH NORMAL VRK2 LEVELS ARE NOT AFFECTED SAYS THIS CONFIRMS THE TUMOR‐SPECIFIC MECHANISM OF THE PROGRAM SIGNIFICANT TUMOR GROWTH INHIBITION OBSERVED WITH VRK1 INHIBITOR OVER 21 DAYS Source text: ID:nMFNbQ48yd Further company coverage: SPRINT.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln